Back to Search
Start Over
Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies
- Source :
- Clinical and Translational Oncology. 22:919-927
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- Immune checkpoint inhibitors (ICIs) show promising clinical activity in advanced cancers. However, the safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies (ANA) are unclear. 191 patients treated with nivolumab, pembrolizumab, atezolizumab, or durvalumab for unresectable advanced cancers between September 2014 and December 2018 were identified retrospectively. Patients were divided into positive (ANA titers ≥ 1:160) and negative ANA groups (ANA titers
- Subjects :
- Adult
Male
musculoskeletal diseases
0301 basic medicine
Cancer Research
medicine.medical_specialty
Durvalumab
Drug-Related Side Effects and Adverse Reactions
Anti-nuclear antibody
Programmed Cell Death 1 Receptor
Pembrolizumab
Polymyositis
Gastroenterology
B7-H1 Antigen
Scleroderma
03 medical and health sciences
Antineoplastic Agents, Immunological
0302 clinical medicine
Atezolizumab
Neoplasms
Internal medicine
medicine
Humans
skin and connective tissue diseases
Immune Checkpoint Inhibitors
Aged
Retrospective Studies
Aged, 80 and over
business.industry
General Medicine
Middle Aged
Dermatomyositis
medicine.disease
stomatognathic diseases
Treatment Outcome
030104 developmental biology
Oncology
Antibodies, Antinuclear
030220 oncology & carcinogenesis
Female
Nivolumab
business
Subjects
Details
- ISSN :
- 16993055 and 1699048X
- Volume :
- 22
- Database :
- OpenAIRE
- Journal :
- Clinical and Translational Oncology
- Accession number :
- edsair.doi.dedup.....6d4907febb537804c5cc26353f83d0e9
- Full Text :
- https://doi.org/10.1007/s12094-019-02214-8